The significance of nonsurgical therapies for cervical infection of high‐risk human papilloma virus: A systematic review and meta‐analysis

Abstract

AbstractObjectiveTo assess whether nonsurgical therapies were related with clearance of cervical infection of high‐risk human papilloma virus (hr‐HPV) or regression of mild abnormal cytology related with hr‐HPV.MethodsUntil March 2023, we identified a total of 10 424 women with cervical infection of hr‐HPV and 1966 women with mild abnormal cytology related with hr‐HPV from 44 studies that met the inclusion criteria.ResultsAfter systematically retrieving literature, we identified 2317 citations and 44 randomized controlled studies (RCT) were enrolled. Cumulative results suggested women with cervical infection of hr‐HPV might benefit from nonsurgical therapies. Both the clearance of hr‐HPV (OR: 3.83, I2 = 99%, p < 0.00001) and regression of mild abnormal cytology related with hr‐HPV (OR: 3.12, I2 = 63%, p < 0.00001) were significantly higher than control group. Subgroup analysis stratified by systematic therapy, topical therapy, traditional Chinese medicines (TCMs), and presistent hr‐HPV got consistent results. There was substantial heterogeneity between trials (I2 = 87% for clearance of hr‐HPV and 63% for regression of cytology), sensitivity analysis was performed by excluding single study one by one, and found the cumulative results were stable and dependable. Both the funnel plots for clearance of hr‐HPV and regression of abnormal cytology were asymmetrical, significant publication bias might exist.ConclusionNonsurgical therapies might benefit women who had a cervical infection of hr‐HPV with/without mild abnormal cytology related with hr‐HPV. Both the clearance of hr‐HPV and regression of abnormal cytology were significantly higher than control group. More studies with less heterogeneity were needed urgently to draw concrete conclusion.